Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL303162 | 1.00 | TDP1 (0.47) | TDP1LMNACNR1EGFRSOAT2 | |
| SCHEMBL2125298 | 1.00 | TDP1 (0.47) | TDP1LMNACNR1EGFRSOAT2 | |
| SCHEMBL303521 | 1.00 | TDP1 (0.47) | TDP1LMNACNR1EGFRSOAT2 | |
| SCHEMBL139446 | 1.00 | TDP1 (0.47) | TDP1LMNACNR1EGFRSOAT2 | |
| SCHEMBL303164 | 1.00 | TDP1 (0.47) | TDP1LMNACNR1EGFRSOAT2 | |
| SCHEMBL302971 | 1.00 | TDP1 (0.47) | TDP1LMNACNR1EGFRSOAT2 | |
| SCHEMBL304116 | 1.00 | TDP1 (0.47) | TDP1LMNACNR1EGFRSOAT2 | |
| SCHEMBL302694 | 1.00 | TDP1 (0.47) | TDP1LMNACNR1EGFRSOAT2 | |
| SCHEMBL5206775 | 1.00 | TDP1 (0.47) | TDP1LMNACNR1EGFRSOAT2 | |
| SCHEMBL302639 | 1.00 | TDP1 (0.47) | TDP1LMNACNR1EGFRSOAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 940 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116848094-A | Tertiary amine lipid compounds and uses thereof | 华南理工大学 | 2023-10-03 | — | — | CN | claimed |
| WO-2023125184-A1 | TERTIARY AMINE LIPID COMPOUND AND USE THEREOF | 华南理工大学 | 2023-07-06 | — | — | WO | claimed |
| CN-107963982-B | Polyisocyanate composition and isocyanate polymer composition | 旭化成株式会社 | 2021-11-12 | — | — | CN | claimed |
| WO-2014071044-A1 | SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE10A) | ALLERGAN, INC. (US) | 2014-05-08 | — | — | WO | claimed |
| EP-2415474-B1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF OPHTHALMIC DISEASES | UBE INDUSTRIES (JP) | 2013-08-28 | — | — | EP | claimed |
| EP-2221308-B1 | BENZAZEPINONE COMPOUND | UBE INDUSTRIES (JP) | 2013-07-10 | — | — | EP | claimed |
| US-8377922-B2 | Benzazepinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-02-19 | — | — | US | claimed |
| US-20120160393-A1 | METHOD FOR MAKING BISTABLE NEMATIC LIQUID-CRYSTAL DEVICES | CDC PROPRIETE INTELLECTUELLE (FR) | 2012-06-28 | — | — | US | claimed |
| US-20120095215-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF EYE DISEASES | UBE INDUSTRIES, LTD. (JP) | 2012-04-19 | — | — | US | claimed |
| EP-2415474-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF OPHTHALMIC DISEASES | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | claimed |
| US-4873263-A | ESTER PRODRUG DERIVATIVES | MERCK & CO., INC. (US) | 1989-10-10 | — | — | US | claimed |
| US-4771073-A | ESTER PRODRUG DERIVATIVES OF L-DOPA, OPTIONALLY WITH A DECARBOXYLASE INHIBITOR | MERCK & CO., INC. (US) | 1988-09-13 | — | — | US | claimed |
| EP-0228253-A1 | Rectally absorbable form of L-dopa | MERCK & CO. INC. (US) | 1987-07-08 | — | — | EP | claimed |
| US-4663349-A | Rectally absorbable form of L-dopa | MERCK & CO., INC. (US) | 1987-05-05 | — | — | US | claimed |
| US-RE31300-E | Process for preparing alkyl- or arylphosphonothioic dihalides | STAUFFER CHEMICAL COMPANY (US) | 1983-07-05 | — | — | US | claimed |
| US-4130583-A | AUTOGENOUS PRESSURE | STAUFFER CHEMICAL COMPANY (US) | 1978-12-19 | — | — | US | claimed |
| US-4052463-A | PROCESS FOR PREPARING TERTIARY PHOSPHINE SULFIDES AND OXIDES | STAUFFER CHEMICAL COMPANY (US) | 1977-10-04 | — | — | US | claimed |
| US-4000190-A | FROM DIALKYL OR DIARYL DISULFIDES, PHOSPHORUS, AND PHOSPHORUS TRIHALIDE | STAUFFER CHEMICAL COMPANY (US) | 1976-12-28 | — | — | US | claimed |
| US-3968156-A | Process for preparing alkyl-or arylphosphonothioic dihalides | STAUFFER CHEMICAL COMPANY (US) | 1976-07-06 | — | — | US | claimed |
| US-3962323-A | PHOSPHORUS TRIHALIDE | STAUFFER CHEMICAL COMPANY (US) | 1976-06-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095215-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF EYE DISEASES | VEGFA, UACA, PGF | TDP1 4753/4885LMNA 2371/4885CNR1 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.